ScoreWhy is Apellis Pharmaceuticals, Inc. ?
1
With a growth in Net Sales of 60.85%, the company declared Outstanding results in Mar 26
- The company has declared positive results for the last 3 consecutive quarters
- OPERATING CASH FLOW(Y) Highest at USD 37.76 MM
- ROCE(HY) Highest at 46.02%
- NET SALES(Q) At USD 268.3 MM has Grown at 60.85%
2
With ROE of 11.21%, it has a expensive valuation with a 6.01 Price to Book Value
- Over the past year, while the stock has generated a return of 150.79%, its profits have risen by 118.1% ; the PEG ratio of the company is 0.5
3
High Institutional Holdings at 100%
- These investors have better capability and resources to analyse fundamentals of companies than most retail investors.
4
Market Beating Performance
- The stock has generated a return of 150.79% in the last 1 year, much higher than market (S&P 500) returns of 28.21%
Real-Time Research ReportHow much should you buy?
- Overall Portfolio exposure to Apellis Pharmaceuticals, Inc. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Apellis Pharmaceuticals, Inc. for you?
High Risk, Low Return
Absolute
Risk Adjusted
Volatility
Apellis Pharmaceuticals, Inc.
150.79%
-0.01
154.67%
S&P 500
22.24%
2.22
12.69%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
31.98%
EBIT Growth (5y)
17.71%
EBIT to Interest (avg)
-15.40
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
0.61
Sales to Capital Employed (avg)
0.94
Tax Ratio
0.60%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
0
ROE (avg)
0
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
54
Industry P/E
Price to Book Value
6.01
EV to EBIT
29.76
EV to EBITDA
29.16
EV to Capital Employed
6.26
EV to Sales
2.35
PEG Ratio
0.46
Dividend Yield
NA
ROCE (Latest)
21.03%
ROE (Latest)
11.21%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
No Signal
Bearish
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Mildly Bullish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
Bullish
Bullish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend24What is working for the Company
OPERATING CASH FLOW(Y)
Highest at USD 37.76 MM
ROCE(HY)
Highest at 46.02%
NET SALES(Q)
At USD 268.3 MM has Grown at 60.85%
PRE-TAX PROFIT(Q)
At USD 19.15 MM has Grown at 120.84%
NET PROFIT(Q)
At USD 18.66 MM has Grown at 120.23%
RAW MATERIAL COST(Y)
Fallen by -7.23% (YoY
0What is not working for the Company
NO KEY NEGATIVE TRIGGERS
Here's what is working for Apellis Pharmaceuticals, Inc.
Operating Cash Flow
Highest at USD 37.76 MM and Grown
In each year in the last three yearsMOJO Watch
The company has generated higher cash revenues from business operations
Operating Cash Flows (USD MM)
Net Sales
At USD 268.3 MM has Grown at 60.85%
Year on Year (YoY)MOJO Watch
Near term sales trend is very positive
Net Sales (USD MM)
Pre-Tax Profit
At USD 19.15 MM has Grown at 120.84%
Year on Year (YoY)MOJO Watch
Near term Pre-Tax Profit trend is very positive
Pre-Tax Profit (USD MM)
Net Profit
At USD 18.66 MM has Grown at 120.23%
Year on Year (YoY)MOJO Watch
Near term Net Profit trend is very positive
Net Profit (USD MM)
Raw Material Cost
Fallen by -7.23% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Here's what is not working for Apellis Pharmaceuticals, Inc.
Non Operating Income
Highest at USD 0.16 MM
in the last five periodsMOJO Watch
Increased income from non business activities may not be sustainable
Non Operating income
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
